Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients

NCT00922688 is registered in ClinicalTrials.gov with Medical Center Alkmaar as lead sponsor.

NCT NCT00922688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00922688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients
Lead sponsor
Medical Center Alkmaar
Phase
Not applicable
Overall status
Unknown status
Start date
December 31, 2010
Completion date
May 31, 2013
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colon carcinoma